InsidersTradesSigma
Follow the Amarin CORP Plc\uk stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Amarin CORP Plc\uk has recorded 168 reports. Market capitalisation: €299m. The latest transaction was disclosed on 3 August 2026 (Levée d'options). Among the most active insiders: Ketchum Steven B. Every trade is free.
168
Insider Decl.
n/a
Thresholds
€247,314
7 ops.
Buy Volume
€25,044
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Amarin CORP Plc\uk Sell (bearish), based on 1 analysts. Average price target: US$12.00.
35Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,956 of 29,062 companies
34.1
score / 100
Value33
Quality35
FCF yld2.3%
Earn yld-13%
EV/EBITDA·
ROE-6.0%
Gross mgn57%
Net mgn-18%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 August 2026
Declarations168 total
313 sharesAmerican Depositary ShareSEC:0001193125-26-330669:0
155 shares@ US$14.26American Depositary ShareSEC:0001193125-26-330669:1
3,688 sharesAmerican Depositary SharesSEC:0001193125-26-304910:0
1,264 shares@ US$15.940.0066% mcap50.0% of flowAmerican Depositary SharesSEC:0001193125-26-304910:1
3,688 sharesAmerican Depositary SharesSEC:0001193125-26-304911:0
1,887 shares@ US$15.940.0098% mcap19.7% of flowAmerican Depositary SharesSEC:0001193125-26-304911:1
3,688 sharesAmerican Depositary SharesSEC:0001193125-26-304912:0
1,926 shares@ US$15.940.010% mcap34.6% of flowAmerican Depositary SharesSEC:0001193125-26-304912:1
2,447 sharesAmerican Depositary SharesSEC:0001193125-26-304914:0
1,206 shares@ US$15.940.0063% mcap33.3% of flowAmerican Depositary SharesSEC:0001193125-26-304914:1
6,250 sharesAmerican Depositary SharesSEC:0001193125-26-290834:0
3,197 sharesAmerican Depositary SharesSEC:0001193125-26-290834:1
838 sharesAmerican Depositary SharesSEC:0001193125-26-170731:0
403 shares@ US$14.980.0018% mcap59.5% of flowAmerican Depositary SharesSEC:0001193125-26-170731:1
838 sharesAmerican Depositary SharesSEC:0001193125-26-167112:0
438 shares@ US$14.980.0018% mcap61.5% of flowAmerican Depositary SharesSEC:0001193125-26-167112:1
838 sharesAmerican Depositary SharesSEC:0001193125-26-167113:0
403 shares@ US$14.980.0017% mcap59.5% of flowAmerican Depositary SharesSEC:0001193125-26-167113:1
838 sharesAmerican Depositary SharesSEC:0001193125-26-167114:0
403 shares@ US$14.980.0017% mcap59.5% of flowAmerican Depositary SharesSEC:0001193125-26-167114:1
838 sharesAmerican Depositary SharesSEC:0001193125-26-167117:0
403 shares@ US$14.980.0017% mcap59.5% of flowAmerican Depositary SharesSEC:0001193125-26-167117:1
838 sharesAmerican Depositary SharesSEC:0001193125-26-167118:0
403 shares@ US$14.980.0017% mcap59.5% of flowAmerican Depositary SharesSEC:0001193125-26-167118:1
838 sharesAmerican Depositary SharesSEC:0001193125-26-167119:0
25 of 168 declarations
关于 Amarin CORP Plc\uk
Amarin Corporation plc（股票代码：AMRN）是一家在美国纳斯达克上市的生物制药公司。对于法语投资者而言，Amarin 最好被理解为一家专注于心血管疾病的制药专家，其投资案例围绕单一旗舰资产：在美国的 VASCEPA® 和国际上的 VAZKEPA®，两者均基于二十碳五烯酸乙酯。公司声明的使命是推进心血管护理并降低高风险患者群体的风险，这使其成为一个高度专注的医疗保健公司，而非一个广泛多元化的制药平台。([amarincorp.com](https://www.amarincorp.com/news-and-media/amarin-reports-2026-first-quarter-financial-results?utm_source=openai)) 从历史角度看，Amarin 在心血管研究和开发领域建立了其身份，其研发总部位于康涅狄格州米斯蒂克。该公司现在从爱尔兰都柏林和新泽西州布里奇沃特进行运营沟通，反映出其具有美国商业根基和全球执行能力的国际企业架构。随着时间的推移，Amarin 已从一个更注重开发的模式转向一个以商业化为主导的模式，专注于最大化 VASCEPA/VAZKEPA 的全球价值。([amarincorp.com](https://www.amarincorp.com/about-amarin?utm_source=openai)) Amarin 的核心业务是二十碳五烯酸乙酯的商业化，这是一种在心血管风险降低方面具有差异化的处方疗法。在美国，管理层强调即使在仿制药进入市场后，该特许经营权仍具有弹性。在国际上，公司越来越依赖许可和供应合作伙伴关系来扩大市场准入，而无需承担逐个国家建立商业基础设施的全部负担。竞争压力来自仿制二十碳五烯酸乙酯产品以及更广泛的血脂管理和心血管风险疗法，因此公司的护城河在很大程度上取决于临床差异化、报销准入和执行力。([amarincorp.com](https://www.amarincorp.com/news-and-media/amarin-reports-2026-first-quarter-financial-results?utm_source=openai)) 从地理上看，Amarin 仍然立足于美国，同时通过多个国家的合作伙伴驱动模式拓展国际业务。公司最近的评论表明，其全球模式已全面合作，覆盖广泛的市场网络，这支持了一种更具资本效率的扩张方式。就市场背景而言，AMRN 在美国纳斯达克上市，这对关注 SEC Form 4 内部交易备案和其他美国披露文件的投资者来说是一个重要细节。([investors.amarincorp.com](https://investors.amarincorp.com/news-releases/news-release-details/amarin-reports-third-quarter-2025-financial-results?utm_source=openai)) 近期里程碑值得关注。2025 年，Amarin 宣布与 Recordati 签订独家许可和供应协议，以在欧洲商业化 VAZKEPA，并强调了额外的 REDUCE-IT 科学分析，并在 2026 年初报告了运营势头有所改善，包括现金流转正早于预期。该公司还表示，已于 2025 年 4 月重新符合纳斯达克的最低出价要求，这对于风险管理和上市稳定性而言具有重要意义。总体而言，Amarin 仍然是一个由其主要产品的商业持久性和国际特许经营权的货币化驱动的专业心血管制药故事。([investors.amarincorp.com](https://investors.amarincorp.com/news-releases/news-release-details/amarin-announces-exclusive-license-and-supply-agreement?utm_source=openai))
